Saroglitazar is a medication used to treat type 2 diabetes mellitus and dyslipidemia, a condition of abnormal levels of fats in the blood. It is currently only approved for use in India by the Drug Controller General of India [Wikipedia].
It works by acting on peroxisome proliferator-activated receptors (PPARs), which are proteins found in cells throughout the body. There are different subtypes of PPARs, and saroglitazar is a dual PPAR agonist, meaning it activates both PPAR alpha (α) and PPAR gamma (γ) [Wikipedia].
- PPAR alpha activation helps to lower triglycerides, a type of fat in the blood.
- PPAR gamma activation improves insulin sensitivity, which helps the body to better use insulin and regulate blood sugar levels.
Here’s a summary of how Saroglitazar works:
- Reduces triglycerides
- Reduces LDL cholesterol
- Reduces VLDL cholesterol
- Reduces non-HDL cholesterol
- Increases HDL cholesterol (the “good” cholesterol)
External Links
Saroglitazar